Contentious thought on a Sunday: Is there any reasons NOT to give neo-adjuvant C(R)Tx prior to resections for locally advanced GI cancer until we have proper genomic/biologic selection markers? I mean "Biology is King" & the time of therapy selects winners quite decently?
#SoMe4Surgery is a global ecosystem. If you want to disseminate your #surgicalresearch or to establish global collaborations, join us and use the hashtag for enhanced visibility
Definitely future is personalized also in peritoneal treatment in appendix but of course ok como-rectal... @PrecisionSo @SPeritoneum @me4_so
Prognostic genomic alt on OS in appendiceal adenocarcinoma Journal of Clinical Oncology https://t.co/5L67L0MOR5
One relevant problems in medicine is commercially driven extension of indication. Often you have overlapping groups, one that needs a treatment, one that wants a treatment. Doctors should respond to needs, not invent indications to cater to „wants“. @PrecisionSo@DrUmeshPrabhu